ha ha, that would be nice, I'd be good to retire then .
@bedger - thanks for chipping in. They said 8% of Q1 22 revenue was accountable to EU. Noting the choice of words, I think EU still contributes a very small part towards revenue, I don't see why they would not have addressed it towards the Q3 22 figures otherwise.
So at this stage I would personally not presume EU sales would fill that gap. Q2, 3 and 4 figures would be crucial for us (noting no other SP driving news is forecasted this year from what is known).
**@bedger: Btw I see your posts on OrthoCell, very interesting company. Researching OrthoCell and Aroa Biosurgery Ltd currently (for my portfolio).
OSX Price at posting:
7.8¢ Sentiment: Buy Disclosure: Held
.
